The estimated Net Worth of Franz B Humer is at least $1.3 Milion dollars as of 30 May 2024. Franz Humer owns over 11,200 units of Allogene Therapeutics Inc stock worth over $742,786 and over the last 7 years he sold ALLO stock worth over $26,208. In addition, he makes $526,308 as Independent Director at Allogene Therapeutics Inc.
Franz has made over 2 trades of the Allogene Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 11,200 units of ALLO stock worth $26,208 on 30 May 2024.
The largest trade he's ever made was buying 30,000 units of Allogene Therapeutics Inc stock on 15 October 2018 worth over $540,000. On average, Franz trades about 1,873 units every 93 days since 2017. As of 30 May 2024 he still owns at least 255,253 units of Allogene Therapeutics Inc stock.
You can see the complete history of Franz Humer stock trades at the bottom of the page.
Dr. Franz B. Humer Ph.D. serves as Independent Director of the Company. Dr. Humer is Chairman of the board of directors of the International Centre for Missing and Exploited Children and Chairman of the Humer Foundation. Dr. Humer previously served as a member of the board of directors of Kite from September 2015 until October 2017. He also served as an independent director of Citigroup Inc. from 2012 until 2018, and Chugai Pharmaceuticals Ltd. (Japan) from 2002 until 2014. He served as Chairman of Diageo plc from 2005 to 2017. In addition, Dr. Humer served as Head of Pharmaceuticals and then as Chief Operating Officer of F. Hoffmann-La Roche Ltd. from 1996 to 1998, prior to serving as Chief Executive Officer of Roche Group from 1998 to 2001 and later as chairman and Chief Executive Officer from 2001 to 2008. His tenure as Chairman of Roche Holding Ltd. extended from 2008 to 2014. Before joining Roche Group, he served on the board of Glaxo Holdings plc and was responsible for research, business development, manufacturing, commercial strategy, and all non-US operations for 13 years. In 1973, Dr. Humer joined Schering Plough Corporation where he held various General Management positions in Latin America and Europe. Dr. Humer attended the University of Innsbruck, where he obtained a Ph.D. in Law, and INSEAD in Fontainebleau, where he obtained an MBA.
As the Independent Director of Allogene Therapeutics Inc, the total compensation of Franz Humer at Allogene Therapeutics Inc is $526,308. There are 14 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.
Franz Humer is 74, he's been the Independent Director of Allogene Therapeutics Inc since 2018. There are 1 older and 19 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun oraz Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include: